Renal sympathetic denervation is a novel, endovascular treatment with potential utility in resistant hypertension. First pioneered in humans in 2010, conflicting data exist regarding the efficacy of this treatment. This article will review the evidence to date, the scientific rationale for sympathetic denervation as a treatment for hypertension and consider other possible conditions where the therapy may be of benefit.
CITATION STYLE
Raphael, C. E. (2014). Renal denervation: potential indications and review of trial data. Clinical Medicine, Journal of the Royal College of Physicians of London, 14(6), s38–s40. https://doi.org/10.7861/clinmedicine.14-6-s38
Mendeley helps you to discover research relevant for your work.